Aurinia Pharmaceuticals Inc (AUPH)
5.05
+0.06
(+1.20%)
USD |
NASDAQ |
Apr 22, 16:00
5.045
0.00 (0.00%)
After-Hours: 20:00
Aurinia Pharmaceuticals Research and Development Expense (Quarterly): 10.23M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.23M |
| September 30, 2023 | 13.60M |
| June 30, 2023 | 12.65M |
| March 31, 2023 | 13.16M |
| December 31, 2022 | 9.87M |
| September 30, 2022 | 10.97M |
| June 30, 2022 | 11.52M |
| March 31, 2022 | 12.62M |
| December 31, 2021 | 11.15M |
| September 30, 2021 | 20.07M |
| June 30, 2021 | 10.09M |
| March 31, 2021 | 9.833M |
| December 31, 2020 | 13.17M |
| September 30, 2020 | 12.24M |
| June 30, 2020 | 11.08M |
| March 31, 2020 | 13.84M |
| December 31, 2019 | 13.29M |
| September 30, 2019 | 17.79M |
| June 30, 2019 | 11.15M |
| March 31, 2019 | 10.63M |
| December 31, 2018 | 10.84M |
| September 30, 2018 | 11.15M |
| June 30, 2018 | 10.50M |
| March 31, 2018 | 8.887M |
| December 31, 2017 | 8.691M |
| Date | Value |
|---|---|
| September 30, 2017 | 10.81M |
| June 30, 2017 | 7.107M |
| March 31, 2017 | 7.325M |
| December 31, 2016 | 5.462M |
| September 30, 2016 | 3.342M |
| June 30, 2016 | 2.406M |
| March 31, 2016 | 3.324M |
| December 31, 2015 | 3.652M |
| September 30, 2015 | 4.67M |
| June 30, 2015 | 4.33M |
| March 31, 2015 | 3.33M |
| December 31, 2014 | 3.092M |
| September 30, 2014 | 2.433M |
| June 30, 2014 | 2.547M |
| March 31, 2014 | 1.04M |
| December 31, 2013 | 0.691M |
| September 30, 2013 | 0.524M |
| June 30, 2013 | 0.442M |
| March 31, 2013 | 0.335M |
| December 31, 2012 | 3.302M |
| September 30, 2012 | 0.5629M |
| June 30, 2012 | 0.8033M |
| March 31, 2012 | 0.8038M |
| December 31, 2011 | 0.9396M |
| September 30, 2011 | 0.743M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.833M
Minimum
Mar 2021
20.07M
Maximum
Sep 2021
12.54M
Average
12.24M
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
| Lexaria Bioscience Corp | 0.2458M |
| Acasti Pharma Inc | 1.443M |
| Edesa Biotech Inc | 0.7045M |
| Xenon Pharmaceuticals Inc | 41.08M |
| ESSA Pharma Inc | 5.377M |